glaxo
glaxosmithkline
global
garnier
generics
grow
growth
good
aims
after
afternoon
anti-depressants
and
at
absorbed
also
allergies
as
high
hit
hivaids
had
he
however
profit
profits
products
progress
price
particularly
paxil
pace
pipeline
pence
performance
fall
failure
firm
for
forward
saw
says
sales
said
share
still
success
such
several
it
its
is
in
important
9%
last
london
lost
look
lift
year
years
to
the
trade
treatment
treatments
trial
terms
£62bn
£15bn
$115bn
but
business
biggest
be
been
europe's
executive
experimental
early
drugmaker
drugs
during
dollar
down
deliver
despite
development
depression
difficult
discontinued
disappointing
diabetes
recovery
research
results
relying
2005
2004
on
of
obesity
over
our
way
was
wellbutrin
weak
were
will
cheap
chief
copies
confident
continuing
conditions
company
can
cancer
clinical
up
1%
1218
new
now
jean-pierre
mr
managing
means
key
known
'771